Physician profile
Devina Bhasin
NPI 1063607109
$25,896.49
in general payments reported to CMS, 2019-2025
28 companies · $9,820 in 2025
The $9,820 reported for 2025 was more than what 79% of Transplant Hepatology providers received nationally (typical 2025 total: $508).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $186 · 2020: $183 · 2021: $64.73 · 2022: $590 · 2023: $759 · 2024: $14K · 2025: $9,820.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Travel and Lodging: $4,756 · Food and Beverage: $4,097 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,000.00 |
| Travel and Lodging | $4,755.50 |
| Food and Beverage | $4,097.10 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $22,330.03 | 2019-2025 | Livdelzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $799.17 | 2019-2025 | Xifaxan, Plenvu |
| Intercept Pharmaceuticals, INC. | $440.14 | 2019-2025 | Ocaliva |
| Abbvie INC. | $353.30 | 2019-2025 | Mavyret |
| Madrigal Pharmaceuticals | $261.31 | 2024-2025 | Rezdiffra, Resmetirom |
| Mallinckrodt Hospital Products INC. | $225.01 | 2023-2025 | Terlivaz, Acthar |
| Amgen INC. | $174.91 | 2025 | Uplizna |
| Alexion Pharmaceuticals, INC. | $160.60 | 2020-2025 | Ultomiris |
| Fujifilm Healthcare Americas Corporation | $153.85 | 2025 | |
| Boston Scientific Corporation | $152.23 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $134.95 | 2024-2025 | Iqirvo, Bylvay |
| Novo Nordisk INC | $112.11 | 2025 | Wegovy |
| Astellas Pharma US INC | $100.23 | 2022-2023 | Cresemba |
| Trisalus Life Sciences, INC. | $68.55 | 2025 | Trinav Infusion System |
| Orphalan INC | $58.49 | 2023-2025 | Cuvrior |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Invivyd INC | $47.50 | 2025 | Pemgarda |
| Ethicon US, LLC | $42.58 | 2025 | Surgicel Nu-Knit, Vistaseal |
| Baxter Healthcare | $41.79 | 2020 | |
| Astrazeneca Pharmaceuticals Lp | $41.15 | 2020-2023 | Lokelma |
| Pfizer INC. | $37.08 | 2023 | |
| Azurity Pharmaceuticals, INC. | $34.88 | 2025 | |
| Sanofi-Aventis U.S. LLC | $27.66 | 2025 | |
| Mirum Pharmaceuticals, INC. | $23.53 | 2025 | Livmarli |
| Kadmon Pharmaceuticals LLC | $21.35 | 2020 | |
| Dynavax Technologies Corporation | $19.22 | 2023 | Heplisav-B |
| Calliditas Therapeutics US INC. | $17.77 | 2023 | Tarpeyo |
| Vifor Pharma, INC. | $17.10 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devina Bhasin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.